Yazar "Yagiz, B." seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    BIOLOGIC DRUG PREFERENCES OF TURKISH RHEUMATOLOGISTS IN SPONDILOARTROPATHY PATIENTS WITH ADVANCED CHRONIC RENAL DISEASE
    (Bmj Publishing Group, 2022) Mercan, R.; Tezcan, M. E.; Yagiz, B.; Ates, A.; Kucuksahin, O.; Bilge, N. S. Yasar; Kanitez, N. A.
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data
    (Clinical & Exper Rheumatology, 2021) Kimyon, G.; Kalyoncu, U.; Kiraz, S.; Bes, C.; Coskun, N.; Yagiz, B.; Kucuksahin, O.
    Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.
  • Küçük Resim Yok
    Öğe
    THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA
    (Bmj Publishing Group, 2022) Gonullu, E.; Kalyoncu, U.; Yagiz, B.; Ates, A.; Kucuksahin, O.; Bilge, S. Yasar; Kanitez, N. A.
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES - IMPLICATIONS FROM TREASURE DATABASE
    (Bmj Publishing Group, 2022) Ersozlu, D.; Ekici, M.; Coskun, B. N.; Badak, S. O.; Bilgin, E.; Kalyoncu, U.; Yagiz, B.
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    PARADOXICAL REACTIONS, ESPECIALLY PSORIASIS IN RHEUMATOLOGY PATIENTS RECEIVING BIOLOGIC THERAPY FROM THE TREASURE DATABASE: A 5-YEAR FOLLOW-UP STUDY
    (Bmj Publishing Group, 2022) Yagiz, B.; Lermi, N.; Coskun, B. N.; Dalkilic, E.; Kiraz, S.; Ertenli, A. I.; Bilgin, E.
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs: real life experience from the TReasure Registry
    (Clinical & Exper Rheumatology, 2024) Karadag, O.; Farisogullari, B.; Yagiz, B.; Erden, A.; Ademoglu, Z.; Kimyon, G.; Bilge, N. S.
    Objective To evaluate the retention rate, treatment response and safety of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR). Methods The TReasure Registry is a multicentre, web-based registry of RA and spondyloarthritis patients across Turkey. DMARD-IR RA patients who received TCZ as first-line biologic treatment were included in this registry for efficacy and safety. Demographic and clinical data, treatments, and adverse events were collected. Drug retention rate was estimated using Kaplan-Meier analysis. Results Among 642 RA patients who ever used TCZ, 258 DMARD-IR RA patients (male/female: 18.2%/81.8%, mean age, 54.41 years) received TCZ as first-line biologic. The median disease duration was 97 (range, 60-179) months and the median TCZ treatment duration was 15 (range, 6-28) months. At the 6th and 12th months of TCZ treatment, the decrease in disease activity scores from baseline was significant. The Kaplan-Meier analysis revealed the retention rate of TCZ at the 12th, 24th, 36th, and 60th months as 81.1%, 73.8%, 66.2%, and 63.6%, respectively. Fifty-seven (22%) patients discontinued TCZ; the main reason being primary or secondary inefficacy (n=29). Conclusion Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies. Significant reductions not only in the disease activity score-28 but also in the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) scores, along with health assessment questionnaire (HAQ) scores, supported the impact of TCZ in RA management with a good safety profile.